Item 1.02 Termination of a Material Definitive Agreement.

On December 4, 2012, Tranzyme, Inc. (the "Company") repaid all principal and interest and made aggregate final payments of approximately $12.9 million and $8.1 million to Oxford Finance LLC, a Delaware limited liability company (as successor-in-interest to Oxford Finance Corporation, a Delaware corporation) ("Oxford"), and Horizon Technology Finance Corporation, a Delaware corporation (as successor-in-interest to Compass Horizon Funding Company LLC, a Delaware limited liability company) ("Horizon"), respectively, pursuant to the Amended and Restated Loan and Security Agreement dated as of January 31, 2012, by and among the Company, Tranzyme Pharma Inc., a Canadian corporation and wholly-owned subsidiary of the Company, Horizon and Oxford (the "Loan Agreement") and terminated the Loan Agreement. The annual interest rate under the Loan Agreement was fixed at 10.0%, contained customary default and acceleration provisions and was secured by the Company's assets, excluding intellectual property. Both Horizon and Oxford hold certain warrants to purchase shares of the Company's common stock. These warrants are immediately exercisable, and excluding certain mergers or acquisitions, will expire on January 30, 2022.

The foregoing description of the Loan Agreement is qualified in its entirety by reference to the Loan Agreement, which is filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed February 1, 2012.

---